Validation of a high-sensitivity assay for zatebradine in dried blood spots of human blood at pg/ml concentrations using HILIC-MS/MS

Bioanalysis

Volumn 2, Issue 11, 2010, Pages 1863-1871

  Michi, Marco ^a   Ferrari, Luca ^a  

^a GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CILOBRADINE; DKAH 269; UNCLASSIFIED DRUG; ZATEBRADINE; BENZAZEPINE DERIVATIVE;

ACCURACY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRIED BLOOD SPOT SAMPLING; DRUG DETERMINATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; INTERMETHOD COMPARISON; MASS SPECTROMETRY; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; BLOOD; BLOOD ANALYSIS; CHEMICAL PHENOMENA; DESICCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; LIMIT OF DETECTION; METHODOLOGY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VALIDATION STUDY;

BENZAZEPINES; BLOOD CHEMICAL ANALYSIS; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESICCATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIMIT OF DETECTION; LINEAR MODELS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 79952493883     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.126     Document Type: Article

References (32)

1. Guthrie R, Suzi A. A simple phenyl analine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32, 338-343 (1963).
2. Ranieri E, Lewis BD, Gerace RL et al. Neonatal screening for cystic fbrosis using immunoreactive trypsinogen and direct gene ana lysis: four years' experience. Br. Med. J. 308, 1469-1472 (1994).
3. Muchamore I, Morphett L, Barlow-Stewart K. Exploring existing and deliberated community perspectives of newborn screening: informing the development of state and national policy standards in newborn screening and the use of dried blood spots. Aust. New Zealand Health Policy 3, 1-9 (2006).
4. Buyukgebiz A. Newborn screening for congenital hypothyroidism. J. Pediatr. Endocrinol. Metab. 19, 1291-1298 (2006). (Pubitemid 44963838)
5. Camilot M, Teofoli F, Vincenzi M, Federici F, Perlini S, Tato L. Implementation of a congenital hypothyroidism newborn screening procedure with mutation detection on genomic DNA extracted from blood spots: the experience of the Italian Northeastern Reference Center. Genet. Test. 11, 387-390 (2007).
6. Fletcher JM, Gerace R, Bartlett B, Harrison JR, Ranieri E. Incorporating 2nd tier tandem mass spectrometry methylmalonic acid testing into routine expanded newborn screening reduces false positives. Mol. Genet. Metab. 98, 108-109 (2009).
7. Marca GL, Malvagia S, Funghini S et al. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program. Rapid Commun. Mass Spectrom. 23, 3891-3893 (2009).
8. Mantikou E, Arkesteijn SG, van Beckhoven JM, Kerkhoffs JL, Harteveld CL, Giordano PC A brief review on newborn screening methods for hemoglobinopathies and preliminary results selecting ß-thalassemia carriers at birth by quantitative estimation of the HbA fraction. Clin. Biochem. 42, 1780-1785 (2009).
9. Weisfeld-Adams JD, Morrissey MA, Kirmse BM et al. Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. Mol. Genet. Metab. 99, 116-123 (2010).
10. Eyles DW, Morley R, Anderson C et al. The utility of neonatal dried blood spots for the assessment of neonatal vitamin D status. Paediatr. Perinat. Epidemiol. 24, 609-610 (2010).
11. Spliethoff HM, Tao L, Shaver SM et al. Use of newborn screening program blood spots for exposure assessment: declining levels of perfuorinated compounds in New York State infants. Environ. Sci. Technol. 42, 5361-5367 (2008).
12. Chaudhuri SN, Butala SJM, Ball RW, Braniff CT. Pilot study for utilization of dried blood spots for screening of lead, mercury and cadmium in newborns. J. Expos. Sci. Environ. Epidemiol. 19, 298-316 (2009).
13. Bergqvist Y, Al Kabbani J, Krysén B, Berggren Palme I, Rombo L. High-performance liquid chromatographic method for the simultaneous determination of mefoquine and its carboxylic metabolite in 100-μ l capillary blood samples dried on paper. J. Chromatogr. B 615, 297-302 (1993). (Pubitemid 23171255)
14. Bergqvist Y, Doverskog M, Kabbani AJ. J. High-performance liquid chromatographic determination of (SR)-and (RS)-enantiomers of mefoquine in plasma and capillary blood sampled on paper after derivatization with (-)-1-(9-fuorenyl)ethyl chloroformate. J. Chromatogr. B 652, 73-81 (1994). (Pubitemid 24079351)
15. Bergqvist Y, Funding L, Kaneko A, Krysén B, Leek T. Improved method for the simultaneous determination of proguanil and its metabolites by high-performance liquid chromatography and solid-phase extraction of 100-μ l capillary blood samples dried on sampling paper. J. Chromatogr. B 719, 141-149 (1998).
16. AbuRuz S, Millership J, McElnay J. Dried blood spot liquid chromatography assay for therapeutic drug monitoring of metformin. J. Chromatogr. B 832, 202-207 (2006). (Pubitemid 43339947)
17. Allanson AL, Cotton MM, Tettey JNA, Boyter AC Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J. Pharm. Biomed. Anal. 44, 963-969 (2007). (Pubitemid 47096856)
18. Blessborn D, Römsing S, Annerberg A et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J. Pharm. Biomed. Anal. 45, 282-287 (2007).
19. Edelbroek PM, Heijden JVD, Stolk LML. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31, 327-336 (2009).
20. Van der Heijden J, de Beer Y, Hoogtanders K et al. Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry J. Pharm. Biomed. Anal. 50, 664-670 (2009).
21. Suyagh MF, Kole PL, Millership J, Collier P, McElnay JC, Halliday H. Development and validation of a dried blood spot-LC-APCI-MS assay for estimation of canrenone in paediatric samples. J. Chromatogr. B 878, 769-776 (2010).
22. Li W, Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative ana lysis of small molecules. Biomed. Chromatogr. 24, 49-65 (2010).
23. Spooner N, Lad R, Barfeld M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 8, 1557-1563 (2009).
24. Mess J-N, Côté C, Bergeron A, Furtado M, Garofolo F. Selection of HILIC columns to handle matrix effect due to phospholipids. Bioanalysis 1(1), 57-62 (2009).
25. Xu RN, Rieser MJ, El-Shourbagy TA. Bioanalytical hydrophilic interaction chromatography: recent challenges, solutions and applications. Bioanalysis 1(1), 239-253 (2009).
26. Hsieh Y, Galviz G, Hwa JJ. Ultra-performance hydrophilic interaction LC-MS/MS for the determination of metformin in mouse plasma. Bioanalysis 1(6), 1073-1079 (2009).
27. Kobinger W, Lillie C Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]me thylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new 'specifc bradycardiac agent'. Eur. J. Pharmacol. 104, 9-18 (1984). (Pubitemid 14006456)
28. Franke H, Su CAP. Clinical pharmacology of two specifc bradycardic agents. Eur. Heart J. 8, 91-98 (1987). (Pubitemid 18088418)
29. Roth W, Bauer E, Heinzel G et al. Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J. Pharm. Sci. 82, 99-106 (1993). (Pubitemid 23148860)
30. Schmid J, Bucheler A, Muller B. Assay of zatebradine in plasma by fully automated sample clean-up, capillary gas chromatography and ammonia chemical ionisation mass spectrometry J. Chromatorg B 658, 93-101 (1994). (Pubitemid 24261965)
31. Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. AAPS Journal. 9, E30-E42 (2007) (Pubitemid 46296546)
32. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (2001).